巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Synlogic

    SYBX
    1.200
    0.000
    0.00%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Synlogic - 延遲價格・最後更新於 23/05 22:00
    最高位
    --
    最低位
    --
    開市價
    --
    前收市價
    1.200
    成交量(千)
    --
    成交額(百萬)
    --
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    84.30
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    4.540 - 1.020
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Synlogic
    證券代碼
    SYBX.US
    所屬板塊
    Biotechnology
    公司業務
    Synlogic Inc is a biopharmaceutical company focused on the discovery and development of Synthetic Biotic medicines which are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways, or deliver combinations of therapeutic factors. Synthetic Biotic medicines are generated from the company's proprietary drug discovery and development platform, using Synthetic Biology and leveraging a reproducible, modular approach to develop beneficial microbes that perform or deliver critical therapeutic functions. Its key product candidate is SYNB1618, an oral therapy intended for the treatment of PKU, a rare metabolic disease in which an amino acid known as phenylalanine accumulates in the body as a result of genetic defects.
    發行量
    69709236
    公司總部
    301 Binney Street, Suite 402
    公司網址
    https://www.synlogictx.com
    公司電郵
    liz@synlogictx.com
    公司電話
    +1 617 401-9975
    暫無內容

    關於

    Synlogic(SYBX.US)所屬的行業板塊為Biotechnology。
    Synlogic Inc is a biopharmaceutical company focused on the discovery and development of Synthetic Biotic medicines which are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways, or deliver combinations of therapeutic factors. Synthetic Biotic medicines are generated from the company's proprietary drug discovery and development platform, using Synthetic Biology and leveraging a reproducible, modular approach to develop beneficial microbes that perform or deliver critical therapeutic functions. Its key product candidate is SYNB1618, an oral therapy intended for the treatment of PKU, a rare metabolic disease in which an amino acid known as phenylalanine accumulates in the body as a result of genetic defects.
    詳細公司背景可參考: https://www.synlogictx.com